If you have been reading about albumin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-30. Numbers and descriptions here follow the published literature rather than marketing material.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
| Property | Value | Notes |
|---|---|---|
| Duration with linker | Several days | Reported in early human work |
| Duration without linker | Tens of minutes | Short plasma residence |
| Albumin attachment site | Cysteine-34 | Covalent maleimide reaction |
| Primary receptor | Pituitary GHRH receptor | Stimulates growth hormone release |
| Downstream marker | Insulin-like growth factor 1 | Indirect measure of activity |
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
Acral persistent papular mucinosis Atypical lichen myxedematosus (intermediate lichen myxedematosus) Atypical tuberous myxedema (Jadassohn–Dosseker syndrome) Cutaneous focal mucinosis Cutaneous lupus mucinosis (papular and nodular mucinosis in lupus erythematosus, papular and nodular mucinosis of Gold, papulonodular mucinosis in lupus erythematosus) Discrete papular lichen myxedematosus Eccrine mucinosis Follicular mucinosis (alopecia mucinosa, mucinosis follicularis, Pinkus' follicular mucinosis, Pinkus' follicular mucinosis–benign primary form) Localized lichen myxedematosus Myxoid cyst (digital mucous cyst, mucous cyst) Myxoid lipoblastoma Neuropathia mucinosa cutanea Nodular lichen myxedematosus Papular mucinosis (generalized lichen myxedematosus, sclerodermoid lichen myxedematosus, scleromyxedema) Papular mucinosis of infancy (cutaneous mucinosis of infancy) Perifollicular mucinosis Reticular erythematous mucinosis (midline mucinosis, plaque-like cutaneous mucinosis, REM syndrome) Scleroderma Self-healing juvenile cutaneous mucinosis Self-healing papular mucinosis Stiff skin syndrome (congenital fascial dystrophy)
If impaired blood flow to the heart lasts long enough, it triggers a process called the ischemic cascade; the heart cells in the territory of the blocked coronary artery die (infarction), chiefly through necrosis, and do not grow back. A collagen scar forms in their place. When an artery is blocked, cells lack oxygen, needed to produce ATP in mitochondria. ATP is required for the maintenance of electrolyte balance, particularly through the Na/K ATPase. This leads to an ischemic cascade of intracellular changes, necrosis and apoptosis of affected cells. Cells in the area with the worst blood supply, just below the inner surface of the heart (endocardium), are most susceptible to damage. Ischemia first affects this region, the subendocardial region, and tissue begins to die within 15–30 minutes of loss of blood supply. The dead tissue is surrounded by a zone of potentially reversible ischemia that progresses to become a full-thickness transmural infarct. The initial "wave" of infarction can take place over 3–4 hours. These changes are seen on gross pathology and cannot be predicted by the presence or absence of Q waves on an ECG. The position, size and extent of an infarct depends on the affected artery, totality of the blockage, duration of the blockage, the presence of collateral blood vessels, oxygen demand, and success of interventional procedures. Tissue death and myocardial scarring alter the normal conduction pathways of the heart and weaken affected areas.
=== Histology === The histologic hallmarks of UIP, as seen in lung tissue under a microscope by a pathologist, are interstitial fibrosis in a "patchwork pattern", honeycomb change and fibroblast foci (see images below).
Sources: en.wikipedia.org
Two rockets targeted Bannu Cantonment with one hitting a Circuit House and the other landing near a mosque. On 11 March, Pakistani officials stated that they had targeted two Taliban border outposts along the border in Zhob sector, forcing Taliban fighters to abandon their positions and seizing several weapons, including Russian-made 73 mm HGL-9 heavy grenade launchers. In border areas adjacent to Shawal in North Waziristan, Pakistani officials stated that they had targeted and destroyed another Taliban border outpost. Pakistani officials also said that since the onset of hostilities, at least 641 Afghan Taliban operatives had been killed and more than 855 injured. According to them, Pakistani forces had destroyed 243 check posts, captured and subsequently destroyed 42 more, destroyed 219 tanks, armored vehicles and artillery guns, and carried out air strikes on 65 locations across Afghanistan. Chinese Foreign Minister Wang Yi, during a telephone conversation with his Pakistani counterpart, said that China resolutely supported Pakistan's fight against terrorism. He added that Chinese officials were working with Taliban and Pakistani officials to find a path toward reconciliation. On the same day, an Afghan media outlet reported that Taliban were looking for a mediator to help end the conflict with Pakistan. Later that day, local sources report that Pakistani forces carried out artillery attacks in parts of Khost province. Taliban officials confirmed the attacks but said that the attacks injured 2 Afghan civilians and destroyed a number of houses.
== Effectiveness == The American Cancer Society states that "There is little scientific evidence available to support proponents' claims that myofascial release relieves pain or restores flexibility" and cautions against using it as a substitute for conventional cancer treatment. The poor quality of research into the use of myofascial release for orthopaedic conditions precludes any conclusions being drawn about its usefulness for this purpose. In 2011, the UK Advertising Standards Authority (ASA) upheld a complaint about claims of effectiveness made in promotional material by Myofascial Release UK health care service. The ASA Council ruled that materials presented by Myofascial Release UK in support of the claims made in their ad were inadequate to establish a "body of robust scientific evidence" to substantiate Myofascial Release UK's range of claims. In addition, the ASA determined that the ad breached advertising rules by introducing a risk that readers might be discouraged from seeking other essential medical treatments. Reviews published in 2013 and 2015 evaluating evidence for MFR's efficacy found that existing clinical trials varied widely in quality, technique, and outcome measures, yielding mixed results. The 2015 review noted: "it is time for scientific evidences on MFR to support its clinical use." Another review concluded that the use of foam rollers or a roller massager before or after exercise for self-myofascial release has been observed to decrease soreness due to DOMS and that self-myofascial release appears to have no negative effect on performance.
=== Multiplexed DIA (plexDIA) === The progress in data independent acquisition (DIA) enabled multiplexed quantitative proteomics with non-isobaric mass tags and a new method called plexDIA introduced in 2021. This new approach increases the number of data points by parallelizing both samples and peptides, thus achieving multiplicative gains. It has the potential to continue scaling proteomic throughput with new mass tags and algorithms. plexDIA is applicable to both bulk and single-cell samples and is particularly powerful for single-cell proteomics.
Sources: en.wikipedia.org
Pantopon, also known as Opium Alkaloids Hydrochlorides, is a preparation of opiates made up of all of the alkaloids present in opium in their natural proportions as hydrochlorides salts. It can sometimes be tolerated by people who are allergic to morphine. Pantopon is prepared by treating standardized medicinal opium with hydrochloric acid or, more commonly, mixing 20 parts morphine HCl, 5 parts codeine, 6 parts thebaine, 8 parts noscapine, 2 parts narcotine, 6 parts miscellaneous alkaloids hydrochlorides. Pantopon is, in other words, opium with all of the tar and other insolubles removed in an injectable form which, by weight, is nearly as potent as morphine. It was invented in 1909 by the Hoffmann-La Roche pharmaceutical company. Other drugs of the same type have included in the opium alkaloid hydrobromides, sulfates, phosphates, and valerates. "Opium in a syringe " and "Injectable Whole Opium" were common advertising slogans for the product from Roche. An example of similar product to Pantopon is Omnopon, which contains morphine, codeine, and papaverine.
The acetylation at position 3 and the conversion into a dihydromorphinone class semisynthetic (at position 14 on the morphine carbon skeleton) allows for the drug to more rapidly enter the central nervous system in greater quantity where it is de-acetylated into hydromorphone, and also converted by other processes into hydromorphinol, morphine and various other active and inactive substances; it therefore simultaneously takes advantage of two methods of increasing the effectiveness of morphine and its derivatives, those being catalytic hydrogenation (codeine into hydrocodone) and esterification (morphine into diamorphine, nicomorphine &c) in a manner not unlike to that of dihydrodiacetylmorphine.
=== Cardiology and cardiovascular outcomes === Truveta data have been used in several cardiovascular studies. A real-world, big-data analysis in the Journal of the Society for Cardiovascular Angiography & Interventions compared ultrasound-assisted catheter-directed therapy (USCDT) with medical therapy for pulmonary embolism (the REAL-PE study), based on data drawn from Truveta-affiliated health systems. A subsequent 2024 analysis in the same journal reported additional real-world findings on USCDT versus standard medical therapy for pulmonary embolism using U.S. health-system records, including those from Truveta-affiliated systems. A 2024 cohort study in JACC: Heart Failure evaluated decongestion strategies in patients hospitalized for heart failure using a large community-based dataset including records from Truveta-affiliated health systems. In 2025, a real-world analysis in the Journal of Cardiac Failure evaluated survival outcomes associated with cardiac contractility modulation devices, using cardiac resynchronization therapy data to validate methodological approaches with large U.S. health-system records, including those from Truveta-affiliated systems.
=== Empirical potentials === Empirical potentials used in chemistry are frequently called force fields, while those used in materials physics are called interatomic potentials. Most force fields in chemistry are empirical and consist of a summation of bonded forces associated with chemical bonds, bond angles, and bond dihedrals, and non-bonded forces associated with van der Waals forces and electrostatic charge. Empirical potentials represent quantum-mechanical effects in a limited way through ad hoc functional approximations. These potentials contain free parameters such as atomic charge, van der Waals parameters reflecting estimates of atomic radius, and equilibrium bond length, angle, and dihedral; these are obtained by fitting against detailed electronic calculations (quantum chemical simulations) or experimental physical properties such as elastic constants, lattice parameters and spectroscopic measurements. Because of the non-local nature of non-bonded interactions, they involve at least weak interactions between all particles in the system. Its calculation is normally the bottleneck in the speed of MD simulations. To lower the computational cost, force fields employ numerical approximations such as shifted cutoff radii, reaction field algorithms, particle mesh Ewald summation, or the newer particle–particle-particle–mesh (P3M). Chemistry force fields commonly employ preset bonding arrangements (an exception being ab initio dynamics), and thus are unable to model the process of chemical bond breaking and reactions explicitly.
Sources: en.wikipedia.org
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.
The group is intended to alter distribution and persistence, not receptor engagement. The peptide portion still binds the pituitary receptor, so the primary difference is duration rather than potency.
Not firmly. Early reports describe several days for the extended form, but independent confirmations are sparse, and values vary with assay method and study design.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.